# ⚔️ CLINICAL TRIAL DOSSIER

**NCT ID**: NCT03916679  
**Trial Title**: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:42:27.322960  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer  
**Phase**:   
**Status**: UNKNOWN  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: 

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT03916679

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/4 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ✅ PASS | 0.90 | Ovarian/gynecologic match: ["ovarian cancer"] |
| Treatment Line | ✅ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ✅ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ✅ PASS | 0.50 | No location data (assume match) |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 100.0%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 100.0%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 100.0%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

- 18 to 70 Years Old, female; Expected survival \> 12 weeks; Clinical performance status of ECOG score 0-2; Patients who have previously been treated with second- line or more lines of standard treatment are not effective (No remission or recurrence after remission); At least one measurable tumor foci according to RECIST standard 1.1 ; Positive Mesothelin expression in tumor tissues; Creatinine ≤ 1.5×ULN; ALT and AST ≤ 3×ULN; Total bilirubin ≤ 2×ULN; Hemoglobin≥90g/L; Absolute counting of neutrophils≥1000uL ; Absolute counting of lymphocytes\>0.7×10\^9/L; Counting of Platelet≥75000/uL; The venous access required for collection can be established without contraindications for leukocyte collection; Able to understand and sign the Informed Consent Document.

### Exclusion Criteria

- Accompanied by other uncontrolled malignant tumors; Active hepatitis B, hepatitis C, syphilis, HIV infection; Suffering severe cardiovascular or respiratory disease; Any other diseases could affect the outcome of this trial; Any affairs could affect the safety of the subjects or outcome of this trial; Pregnant or lactating women, or patients who plan to be pregnancy during or after treatment; There are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; Patients who are accounted by researchers to be not appropriate for this test; Received CAR-T treatment or other gene therapies before assignment; Subject suffering disease affects the understanding of informed consent or comply with study protocol.

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

